Lower expression of NOTCH components in peripheral blood mononuclear cells of allogeneic hematopoietic cell transplant patients.

Autor:	Colella MP; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil., Morini BC; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil., Niemann F; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil., Lopes MR; Universidade Federal do Vale do São Francisco (Univasf), Paulo Afonso, BA, Brazil., Saad SO; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil., Favaro P; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil; Universidade Federal de São Paulo, (Unifesp), Diadema, SP, Brazil. Electronic address: favaropb@gmail.com.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2023 Jul-Sep; Vol. 45 (3), pp. 324-329. Date of Electronic Publication: 2022 Jun 17.
DOI:	10.1016/j.htct.2022.05.005
Abstrakt:	Introduction: Chronic graft-versus-host disease (cGvHD) not only remains the main cause of late mortality after allogeneic hematopoietic cell transplant, but also has the capacity of causing severe organ impairment in those who survive. The Notch, a highly conserved ligand-receptor pathway, is involved in many immunological processes, including inflammatory and regulatory responses. Recently, mouse models have shown that the blockage of canonical Notch signaling prevents GvHD. Objective and Method: Due to the lack of data on the Notch pathway in human chronic GvHD, we sought to study the expression of NOTCH components in primary samples of patients who received allo-HCT and presented active cGvHD or a long-term clinical tolerance to cGvHD. Results: Our results showed a significantly lower expression of NOTCH components in both groups that received allo-HCT, independently of their cGvHD status, when compared to healthy controls. Conclusion: Moreover, there were no differences in gene expression levels between the active cGvHD and clinically tolerant groups. To our knowledge, this is one of the first studies performed in human primary samples and our data indicate that much remains to be learned regarding NOTCH signaling as a new regulator of GvHD. Competing Interests: Conflicts of interest None. (Copyright © 2022. Published by Elsevier España, S.L.U.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu